BUDAPEST, Hungary, LONDON and PRINCETON, N.J., Oct. 6 ThalesNano, Inc. today announced that it has signed agreements with a numberof academic organizations including the Scripps Research Institute, theUniversity of California, San Francisco, Boston University, Temple Universityand the University of Texas at Arlington. These institutions join the top 20pharmaceutical companies, who have all deployed ThalesNano's H-Cube.
The H-Cube Hydrogenation Reactor is a bench-top standalone device,uniquely combining continuous-flow chemistry with endogenous hydrogengeneration and a disposable catalyst cartridge system. At about a foot wide,and with the flexibility to use a vastly extended range of conditions comparedto traditional techniques without any safety concerns, the H-Cube system isideally suited to educational and to academic research laboratories.
Professor Phil Baran of the Scripps Research Institute explains, "TheH-Cube has already had a dramatic effect on our research and that of severalgroups at Scripps. We believe the H-Cube will soon be as essential as an HPLCin the toolkit of a modern organic chemistry laboratory."
Added Dr. Chris O'Brien of the University of Texas at Arlington, "My groupnow take for granted that they can perform high pressure, high temperaturehydrogenations with ease in a fume hood. To do these reactions conventionallyrequires substantial safety precautions and training. As testament to theH-Cube Midi's ease-of-use and scalability, high pressure hydrogenations arenow routinely performed by undergraduates to yield 10s of grams of finalproduct. H-Cube technology is a must-have for any synthetic laboratory."
"We believe that collaboration with leading universities will serve theentire chemistry community," said Dr. Laszlo Urge, CEO of ThalesNano, Inc."These universities are teaching future generations about the alternativediscovery methods and novel environmentally friendly technologies. We aredelighted to work with these institutions who share our common vision oftransforming the way that chemical entities are discovered. Their experiencewill further enhance the repertoire of published H-Cube reactions, which willprovide great benefit to our community of academic and commercial users."
Dr. Ferenc Darvas, President and Chairman of ThalesNano, Inc. reflected,"The fact that our technology is seeing such wide acceptance in academiagalvanizes H-Cube's position as the new paradigm for efficient hydrogenation.These schools are at the forefront in helping other academic institutions andthe industry to realize the benefits of continuous flow technology in thefuture."
For more information please go to: http://www.thalesnano.com
About ThalesNano, Inc.:
ThalesNano is a world-leading provider of continuous process chemistryinstruments in the rapidly developing market of laboratory and process scaleflow reactors. The company has the widest portfolio of bench-top continuousprocess instruments. Its R&D 100 award winning H-Cube(R) continuous-flowhydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) areused in hundreds of laboratories in four continents and have become the newindustry standard for hydrogenation. 20 out of 20 of the largestpharmaceutical companies in the world employ ThalesNano products andtechnologies.
SOURCE ThalesNano, Inc.